Today: 8 June 2026
Redwire Stock Just Jumped 27% — The $498 Million Number Traders Can’t Ignore
17 May 2026
2 mins read

Redwire Stock Just Jumped 27% — The $498 Million Number Traders Can’t Ignore

New York, May 17, 2026, 11:01 EDT

Redwire Corp heads into the new U.S. trading week after a 27% five-session climb, as investors weighed a record order backlog and fresh defense-drone attention against a still-wide quarterly loss and a new share-sale program.

There was no Sunday trading. The New York Stock Exchange’s core session runs on regular weekdays from 9:30 a.m. to 4 p.m. Eastern time, putting the next cash-market test on Monday, May 18. Redwire closed Friday at $14.06, up from $11.07 on May 8; the sharper move came Thursday, when the stock rose 22.08% on volume of nearly 67.9 million shares.

The move matters now because Redwire is trying to recast itself from a niche space-hardware name into a broader space-and-defense technology contractor. The company reported first-quarter revenue of $97.0 million, up 57.9% from a year earlier, and said backlog reached $498.1 million.

Backlog is work already ordered but not yet recognized as revenue. Redwire also reported a book-to-bill ratio of 1.92, meaning orders booked in the period were nearly twice the revenue recorded. Chief Executive Peter Cannito said the company was seeing “very strong demand,” while pointing to orders in spacecraft, solar arrays and small uncrewed aircraft systems. Redwire Corporation

The defense angle will be visible this week. Redwire says it will show its Stalker and Penguin UAS, or uncrewed aerial systems, along with Octopus optical camera payloads, at SOF Week in Tampa from May 18 to May 21.

Redwire’s rally did not happen in a quiet tape. Rocket Lab, another public space name, surged earlier this month after a revenue beat and what Investor’s Business Daily called its largest launch contract to date; AST SpaceMobile, meanwhile, traded around its own first-quarter report and concerns over launch delays.

The numbers were not clean. Redwire posted a first-quarter net loss of $76.5 million, compared with a loss of $2.9 million a year earlier, while selling, general and administrative costs rose sharply. Its filing said the revenue increase was driven in large part by the Edge Autonomy acquisition, but that acquisition also brought accelerated equity-compensation costs.

Chief Financial Officer Chris Edmunds, on the earnings call, said gross margin improvement remained a focus and that Redwire had cut cash burn. He also said the company was increasing internal research and development spending to meet demand tied to programs such as the $1.8 billion Andromeda IDIQ, a government-style contract vehicle that allows future orders but does not by itself guarantee all revenue.

One overhang is dilution. Redwire disclosed a new at-the-market, or ATM, program allowing it to sell up to $350 million of common stock over time; an ATM program lets a company issue shares into the market rather than in one large deal. The company said proceeds could fund working capital, capital spending, debt repayment, acquisitions or other corporate uses.

Analysts were still active after the report. StockAnalysis cited The Fly as saying Canaccord’s Austin Moeller raised his Redwire price target to $14 from $12 while keeping a Buy rating, and Jefferies’ Greg Konrad lifted his target to $13 from $12 with the same rating. Redwire lists Moeller and Konrad among the analysts covering the company.

But the rally leaves less room for error. Redwire is still loss-making, its adjusted EBITDA was negative in the quarter, and any heavy use of the ATM program could pressure shareholders if new stock is sold into strength. The company’s filing also points to ordinary-course litigation and contract-audit risks tied to government work, a reminder that backlog still has to convert into cash.

The week ahead is light on scheduled financial news but not empty. Redwire’s annual shareholder meeting is set for Wednesday, May 20, at 10 a.m. EDT, giving investors a near-term forum to watch for comments on backlog conversion, Edge Autonomy integration and the pace of defense-tech orders.

Stock Market Today

  • Zealand Pharma Shares Drop 20% After Trial Users Quit Weight-Loss Drug
    June 8, 2026, 4:55 AM EDT. Zealand Pharma's stock fell 20% in Copenhagen trading after the company reported that 20% of participants in a trial of its weight-loss drug stopped treatment due to gastrointestinal side effects. The high dropout rate raised concerns over the drug's tolerability, prompting investor caution. Zealand Pharma's announcement highlighted challenges in retaining patients during clinical trials, a key factor influencing the drug's market potential and future sales. The decline underscores the sensitivity of biotech stocks to trial outcomes and patient adherence issues.

Latest articles

Nokia drops after fast AI rally, traders stay focused

Nokia rally stalls as traders sell tech stocks after AI push

8 June 2026
Nokia shares plunged 2.98% in Helsinki to 12.690 euros, extending losses as investors dumped AI-linked tech stocks amid rising oil prices and rate fears; U.S. ADRs dropped 13.48% Friday, while no new operating update was given and Nokia issued 500 million euros in new debt, with the next key earnings test set for July 23.
SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

8 June 2026
SpaceX’s $75 billion IPO launches June 12 at $135 a share, with retail demand already double the shares on offer and 30% of the deal earmarked for individuals, but 2025 losses of $4.94 billion and a $1.75 trillion target valuation raise questions about post-IPO pricing as index entry and profitability remain uncertain.
Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

8 June 2026
Eli Lilly closed at $1,131.42, up 0.55%, after releasing late-stage data showing its obesity drug retatrutide led to 28.3% weight loss over 80 weeks and reduced sleep apnea and knee pain, fueling hopes its obesity pipeline could expand beyond weight loss as rivals Boehringer Ingelheim and Zealand Pharma unveiled competing data, setting up a key test for Lilly’s trillion-dollar valuation as trading resumes.
SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

8 June 2026
SK Hynix plunged 7.68% to 1,911,000 won despite sealing a multi-year Nvidia memory deal, as fears of a U.S. rate hike and a tech stock rout triggered circuit breakers and an 8.3% KOSPI crash, overshadowing strong AI demand and ongoing HBM supply constraints.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 08.06.2026

8 June 2026
LIVEMarkets rolling coverageStarted: June 8, 2026, 4:00 AM EDTUpdated: June 8, 2026, 4:55 AM EDT Zealand Pharma Shares Drop 20% After Trial Users Quit Weight-Loss Drug June 8, 2026, 4:55 AM EDT.Zealand Pharma’s stock fell 20% in Copenhagen trading after the company reported that 20% of participants in a trial of its weight-loss drug stopped treatment due to gastrointestinal side effects. The high dropout rate raised concerns over the drug’s tolerability, prompting investor caution. Zealand Pharma’s announcement highlighted challenges in retaining patients during clinical trials, a key factor influencing the drug’s market potential and future sales. The decline underscores the
Apple Breaks $300 Line; Investors Watch What’s Next Beyond the iPhone
Previous Story

Apple Breaks $300 Line; Investors Watch What’s Next Beyond the iPhone

Tesla Stock Gets a Weekend Shock as Model Y Prices Rise After Friday Slide
Next Story

Tesla Stock Gets a Weekend Shock as Model Y Prices Rise After Friday Slide

Go toTop